36022391_Infographic_Xevinapant_Trilynx_Design_Manuscript_v20.1.pdf (2.19 MB)

Infographic – Summary of the TrilynX phase 3 study design

figure

posted on 2022-02-17, 11:05 authored by Jean Bourhis, Barbara Burtness, Lisa Francesca Licitra, Christopher M. Nutting, Jonathan D. Schoenfeld, Mokhtar Omar, Florilene Bouisset, Heidi Nauwelaerts, Yulia Urfer, Claudio Zanna, Ezra E.W. Cohen

Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase 3 study design

Funding

Merck

History

Usage metrics

Future Oncology

Keywords

xevinapant chemoradiotherapy inhibitor of apoptosis proteins locally advanced squamous cell carcinoma of the head and neck oropharynx hypopharynx larynx Cancer Therapy (excl. Chemotherapy and Radiation Therapy)

Licence

CC BY-NC-ND 4.0